imaging shows changes in metabolism.
Lancet Oncol. 2006 Nov;7(11):890.
|Silverman, D., et al.|
frontocortical, cerebellar, and basal ganglia activity in
adjuvant-treated breast cancer survivors 5-10 years after
Breast Cancer Research and Treatment 103, no. 3 Epub 2006: 303-311.
Imaging studies conducted in breast cancer survivors five to 10 years after they had undergone chemotherapy showed that the “chemo brain” syndrome of forgetfulness and mental fog that many of these patients experience is rooted in significant alterations of brain function. The changes were worse for patients treated with adjuvant regimens that included tamoxifen.
“People with chemo brain often can’t focus, remember things, or multitask the way they did before chemotherapy,” said lead investigator Daniel H. S. Silverman, MD, PhD. “Our study demonstrates for the first time that patients suffering from these cognitive symptoms have specific alterations in brain metabolism.” Dr. Silverman is Head of Neuronuclear Imaging and Associate Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine at the University of California, Los Angeles. He and his research team published their findings in the September 29 online edition of Breast Cancer Research and Treatment